OF
REGN icon

Optimize Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Optimize Financial’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-749
Closed -$578K – 430
2025
Q4 		$578K Buy
749
+8
+1% +$5.43K 0.29% 91
2025
Q3 		$417K Buy
+741
New +$419K 0.22% 194

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Optimize Financial's REGN Position: Q1 2026 in Review

Optimize Financial sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 749 shares — an estimated $578K sold.

Optimize Financial first reported a position in REGN in Q3 2025 and held it in 2 quarters. The position peaked at $578K in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Optimize Financial reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Optimize Financial sold 749 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $578K.
  • Optimize Financial first reported a position in Regeneron Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Optimize Financial's Regeneron Pharmaceuticals position peaked at $578K in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Optimize Financial's 13F filing for Q1 2026, filed 12 May 2026.